Read DDW’s insights into whether AI can deliver better immunotherapies for cancer, and predictions on what to expect from the sector in 2024
65LAB, a unique partnership of global investors ClavystBio, Leaps by Bayer, Lightstone Ventures, Polaris Partners and the Polaris Innovation Fund alongside Evotec, has funded
Recipient Professor Enrico Petretto from Duke-NUS is spearheading groundbreaking research to develop new drugs for lung disease and uncover new therapeutic targets for kidney
Recipient Associate Professor Lena Ho spearheads groundbreaking research to develop first-in-class therapeutics to target inflammatory diseases Collaboration between 65LAB and Duke-NUS aims to advance
79 Science Park Drive
Cintech IV, #04-05
Singapore 118264
2023 © Copyright of 65LAB